Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box protein 38 (FBXO38) is a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex, responsible for the targeted ubiquitination and proteasomal degradation of select substrates. It was initially identified as a coactivator of the transcription factor KLF7 and is involved in neuronal development, spermatogenesis, and centromere integrity by targeting proteins ZXDA and ZXDB for degradation. FBXO38 has been reported to regulate immune checkpoint protein PD-1 in some studies; however, this role is disputed and considered unconfirmed by recent research. Mutations in the FBXO38 gene are linked to early-onset motor neuron diseases and other pathologies such as chronic inflammatory diseases. There are currently no drugs directly targeting FBXO38, and its role as a therapeutic target remains unestablished.
Not applicable—no specific drugs are documented to target FBXO38 in clinical or preclinical studies
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box protein 38 (FBXO38).